1.8 reviewing the fip transforming vaccination programme

FIP Transforming Vaccination Globally & Regionally

Series 1 Identifying transformation needs

1.8 Reviewing the FIP Transforming Vaccination Programme: Enabling and supporting our profession

Announcements

This webinar is being recorded and live-streamed via Facebook

The recording will be freely available on our website www.fip.org

You may ask questions using the question box provided

You are welcome to provide feedback to [email protected]

Become a member of FIP at www.fip.org/membership_registration

©FIP: All the information in this video are confidential and cannot be copied, downloaded or

reproduced without the formal approval of FIP (International Pharmaceutical Federation).

http://www.fip.org/

mailto:[email protected]

http://www.fip.org/membership_registration

Sponsored by

Sponsored by Pfizer

Introducing the chairs & reflections from FIP leadership

Dominique Jordan

President - FIP

Catherine Duggan

CEO - FIP

Sponsored by

FIP President opening remarks: Dominique Jordan

Sponsored by

Sponsored by Pfizer

Welcome to the “Transforming Vaccination

Regionally & Globally” Programme

Transforming Vaccination Regionally and Globally is the first FIP Transformation outcome-based online programme of its kind underpinned by the FIP Development Goals (FIP DGs).

Final outcome of the programme is a historic global FIP Commitment to Action on Vaccination in Pharmacy.

A FIP Transforming Vaccination Collection (2021)

Sponsored by

Important Links & Resources

Engage with us and help us answer the following questions:

1. What single factor should be prioritized to transform pharmacy

vaccination services globally and regionally?

2. What would be the most important achievement in terms of

pharmacy vaccination services in your country in the next five years?

3. What else should the FIP Commitment to action outline?

Transforming Vaccination Regionally & Globally Webpage

transformingvaccination.fip.org

Sponsored by

Sponsored by Pfizer

To summarize series one, identifying the path

forward that will empower pharmacists and

pharmaceutical scientists to contribute to

improved vaccination uptake and outcomes

Today’s Learning Objective

Sponsored by

Sponsored by Pfizer

Sponsored by

Sponsored by Pfizer

Series 1 summaryScope Event title Date

ZOOM

attendees

Facebook

attendees

Series Initiator

Introducing the FIP ‘Transforming Vaccination

Globally & Regionally’ series Programme…

needs, action and outcomes

25th September 2020

≈ 1k > 10k

Practice

Transforming practice: A focus on strategy &

policy for global change

1st October 2020

Enabling practice: Empowering pharmacists &

removing barriers

2nd October 2020

Science

Addressing barriers to uptake: Adherence,

misinformation, & anti-Science

5th October 2020

From smallpox to COVID-19: Vaccine

development & innovation

6th October 2020

Workforce & Education

Transforming our workforce: Evolving the

pharmacist’s qualification

14th October 2020

Enabling our workforce: Supporting ongoing

competence

15th October 2020

Series Finale

Reviewing the FIP Transforming

Vaccination Programme: Enabling and supporting

our profession

21st October 2020

We are here

Sponsored by

Sponsored by Pfizer

Series 1 summary –

List of Member Organisations engaged in the programmeMembers Country Region

Jordanian Pharmacists Association Jordan Eastern

Mediterranean

Lithuanian Pharmaceutical Association Lithuania Europe

Indian Pharmaceutical Association India South-East Asia

Pharmaceutical Society of Singapore Singapore Western Pacific

Pakistan Pharmacists Association Pakistan Eastern

Mediterranean

Royal Pharmaceutical Society UK Europe

American Pharmacists Association (APhA)

United States Pharmacopeia (USP)

USA Americas

Colegio de Farmacéuticos de Costa Rica Costa Rica Americas

Global Partners

Pharmapod

IPSF

Sponsored by

Sponsored by Pfizer

Series 1 summary – List of Academic Institutional Members

AIM Country

University of Costa Rica Costa Rica

University College London UK

Monash University

University of Sydney

Queensland University of Technology

Australia

St. Louis College of Pharmacy

University of Colorado

USA

National University of Singapore Singapore

Sponsored by

Sponsored by Pfizer

Event 1.2

Sponsored by

WHO Immunisation Agenda 2030:

A Global Strategy to Leave No One Behind

With input from FIP and

IFAA

Sponsored by

Sponsored by

Launch of the FIP call to action to expand the role of

community pharmacies in vaccination, including against

COVID-19 and other future pandemics

Sponsored by

Sponsored by Pfizer

Event 1.2

Sponsored by

Sponsored by Pfizer

Event 1.3

Sponsored by

Sponsored by Pfizer

Identifying transformative needs

Scope: Practice

Ema PaulinoFIP Professional Secretary

Paul SinclairFIP Chair, Board of Pharmaceutical Practice

Sponsored by

Sponsored by Pfizer

Themes and topics covered

Learnings from countries where vaccination services by pharmacists have been or are in the process of being approved.

Event 1.2 Transforming practice: A focus on strategy & policy for global change -

Sponsored by

Sponsored by Pfizer

5 primary take-away messages

1) Singapore: major differences in infrastructure between community pharmacies and government provided services: inconsistencies in vaccination documentation; working in a number of barriers, including legislation, access to vaccination record, infrastructure and training resources and public perception with strong advocacy in social media and public healthcare institutions.

2) Pakistan: No legislative support for pharmacists to vaccinate. Pharmacists slowly being integrated into primary health care facilities.No shared patient record. Advocacy role of organizations important.

Event 1.2 Transforming practice: A focus on strategy & policy for global change

Sponsored by

Sponsored by Pfizer


3) India: barriers: excessive workload, shortage of staff, lack of training and lack of legislation to support vaccination initiativeCovid-19 vaccine will be huge opportunity.

4) Lithuania: pharmacists are viewed as healthcare professionals but not healthcare providers. Vaccination service a great opportunity to change this perception/reality. Pharmacists have no access to health care records. Highlighted importance of finding key players and opinion leaders to advocate and/or support pharmacy immunization.

5) Jordan: have succeeded in having Pharmacist vaccination approved - needed to make discussions with ministry and health bureaucrats part of entire journey. Local pharmacist association very proactive in developing guidelines and immunisation training modules.


Sponsored by

Sponsored by Pfizer

Needs identified

FIP can help in the advocacy process. Webinar participants looking to other countries to help with training resources and infrastructure requisites.

Maybe identify a stepwise approach based on MO experience towards the advocacy/legislative process- FIP toolkit.


Sponsored by

Sponsored by Pfizer

Key takeaway points to include in event collection

Starting the process can seem overwhelming - encourage small steps approach and trial basis as a starting point.


Sponsored by

Sponsored by Pfizer


Health economic considerations, Pharmacists in earlier pandemics and technical requirements of vaccination delivery.

Event 1.3 Enabling practice: Empowering pharmacists & removing barriers

Sponsored by

Sponsored by Pfizer


1) Health economic considerations very important - cost benefits of pharmacist vaccination useful to advocate for expanded role & remuneration critical to program sustainability

2) Consider funding based on outcomes: Establish value of services by outcomes delivered


Sponsored by

Sponsored by Pfizer


3) Start any campaign to broaden scope of pharmacist practice (eg vaccination) with 1) a small manageable trial, 2) a thorough evaluation of trial, and then 3) base advocacy on trial results

4) Must establish suitable legal and technical framework - the FIP toolkit provides support to gather information critical for implementation

5) Pharmacists must create a “credible” service - must be at least a comparable experience for the patient as seeing their doctor/nurse for vaccination


Sponsored by

Sponsored by Pfizer

Needs identified

- Define a structure for approach by an MO to start the journey.

- Share successful examples.


Sponsored by

Sponsored by Pfizer

Key takeaway points

Advocate - trial - evaluate - further advocacy needed.

Comments/Notes:Health economic considerations critical - these can drive the start of the process and will ensure its sustainability.


Sponsored by

Sponsored by Pfizer

Event 1.4

Sponsored by

Sponsored by Pfizer

Event 1.5

Sponsored by

Sponsored by Pfizer


Scope: Science

Giovanni PaulettiFIP Scientific SecretaryChair, Department of Pharmaceutical & Administrative Sciences, St. Louis College of Pharmacy

Ross McKinnonChair of FIP Board of Pharmaceutical Science (BPS)Strategic Professor in Cancer Research & Mathew Flinders Distinguished Professor, College of Medicine and Public Health, Australia)

Sponsored by

Event Summary

• Vaccine production Multiple platforms including established, new and unproven technologies

Quality standards associated with manufacturing/distribution systems

• Development timelines Covid-19 demanded vaccines in record time – large number – most will fail

Vaccine development accelerated using staggered and overlapping clinical pathways

Major factor in accelerated pathways is financial risk of companies rather than

compromising safety

• Unanswered questions Dosing schedules, License pathways, Bottlenecks in production/roll out

Interviews with Professor Nikolai Petrovsky and Professor Colin Pouton

Event 1.4 Addressing barriers to uptake: Adherence, misinformation, & anti-science

Sponsored by

Event Summary

Key Message: Vaccine development is proceeding at accelerated rates across multiple platforms and jurisdictions.

Main needs identified: Adequate funding to assure success of accelerated development programs.

Scale up of production on a global scale (possibly with new platforms)

Key Change: Need to ensure science is informing political discourse related to vaccine development.

Interviews with Professor Nikolai Petrovsky and Professor Colin Pouton

Event 1.4 Addressing barriers to uptake: Adherence, misinformation, & anti-science

Sponsored by

Event Summary

• Quality standards for biologics such as vaccines Performance standards that not binary

Quality standards associated with manufacturing/distribution systems

• Analytical method development for vaccines Need for adaptation due to evolving product over time

Acceptance of variability due to complex composition

• Vulnerability of pharmaceutical supply chain Collect information on global supply chain to identify limitations

Focus on supply of medicine after manufacturing to assure access for patients

Interview with Dr. Ronald T. Piervincenzi

Event 1.5 From smallpox to COVID-19: Vaccine development & innovation

Sponsored by

Event Summary

Key Message: Vaccines represent chemically complex pharmaceutical products that may change in composition

periodically. This can lead to challenges with quality standards and renders vaccines vulnerable to supply

chain disruptions.

Main need identified: Access to scientific information collected during vaccine development

Key Change: Sharing scientific information while protecting intellectual property

Interview with Dr. Ronald T. Piervincenzi

Event 1.5 From smallpox to COVID-19: Vaccine development & innovation

Sponsored by

Sponsored by Pfizer

Event 1.6

Sponsored by

Sponsored by Pfizer

Event 1.7

https://transformingvaccination.fip.org/

Sponsored by

Sponsored by Pfizer


Scope: Workforce & education

Ian BatesDirector of the FIP Workforce Development Hub

Chair of pharmacy education- UCL

Ralph J. AltiereChair of FIP Education (FIPEd)

Dean- University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

Sponsored by

Sponsored by Pfizer


Workforce & Education Needs: Focus On

Undergraduate Education – preparing the future

workforce for providing immunization services

Event 1.6 Transforming our workforce: Evolving the pharmacist’s qualification

Sponsored by

Sponsored by Pfizer


1) Advocacy with government, regulators, professional organizations, other healthcare professionals is critical to gain approval for pharmacists to provide vaccinations and for education and training of undergraduates. Assure pharmacy is represented on immunization decision making groups.

2) Collaborate with countries that have established vaccination education and training programs and adapt to your country needs. FIP can play a role in facilitating such collaborations.


Sponsored by

Sponsored by Pfizer


3) There are important interprofessional education opportunities through collaborations with nursing and medical schools

4) Training must include preparation for adverse events, CPR (Cardiopulmonary resuscitation) /BCLS (Basic Cardiac Life Support) training and establishing the right environment for vaccinations in the pharmacy among many other areas

5) Student perspective is that robust vaccination training must be included in the curriculum to assure students are ready to provide vaccinations upon registration as a pharmacist


Sponsored by

Sponsored by Pfizer

Needs identified

Guidance or frameworks for countries that are developing education

and training programs for students and pharmacists to provide

vaccinations that includes advocacy efforts and training programs

that can be adapted to the needs of countries.


Sponsored by

Sponsored by Pfizer

Key takeaway points

Education and training of both students and practitioners is needed

to achieve the commonly held goal of pharmacist provided

vaccinations.

Development of these training programs requires advocacy efforts

across all sectors to support pharmacists’ roles in vaccinations and

can be facilitated by collaboration with partners in countries with

established immunisation training programs.

FIP plays a key role in facilitating such collaborations.


Sponsored by

Sponsored by Pfizer


Workforce development & training for vaccination services

Event 1.7 Enabling our workforce: Supporting ongoing competence

Sponsored by

Sponsored by Pfizer


1) Training the Trainers is key to starting and sustaining vaccination delivery education & training (E&T)

2) There is variance regarding the global examples of training programmes –content, length, scope

3) There is variance regarding regulatory/mandatory aspects of vaccination training

Sponsored by

Sponsored by Pfizer


4) The imminent launch of the WHO Global Competencies for Universal Health Coverage will add weighting and structure for global support for vaccination training; the FIP Global Competency Framework (GbCF) will be an additional tool in this context to directly support national training programmes.

5) FIP should consider a globally consented structural framework for vaccination training for pre- and post-registration training for vaccination services. This would directly support Member Organisations in developing/sustaining routine vaccination training for service delivery.

Sponsored by

Sponsored by Pfizer

Needs identified

A consented global training framework guidelines, for all nations and Member Organisations, linked with WHO competencies for universal health coverage, for all segments of the pharmacy workforce, using the widely accepted FIP design principles of ‘adopt and adapt’.

FIP plays a key role in facilitating this.

Sponsored by

Sponsored by Pfizer

Key takeaway points

Vaccination training for services have common goals and outcomes.

Global policy should be a two-way focus on developing

competencies as routine curriculum content for all initial education &

training university programmes, and additionally as a workforce

development goal for the untrained mature workforce currently in

practice.

Special FIP global support should be aligned with low and middle income members.

Sponsored by

Sponsored by Pfizer

Young Pharmacists Group (YPG) Perspective

Dr. Allie Jo Shipman

YPG Liaison to FIP Community Pharmacy Section

Director, State PolicyNational Alliance of State Pharmacy Associations

Sponsored by

Sponsored by Pfizer

Educational Opportunities

• Inclusion in curriculum

• Employer support

• Conferences and events

Engaging Young Pharmacists and Students

Sponsored by

Sponsored by Pfizer

Leadership Opportunities

• Inclusion in planning/decision-making

• Project leads/coordinators

• Reverse mentoring

Engaging Young Pharmacists and Students

Sponsored by

Sponsored by Pfizer

Sponsored by

The FIP Development Goals reiterate FIP’s commitment to global health.

Sponsored by

Regional roadmaps.

Indicators & country level metrics.

FIP Transformation programmes.

Global mechanisms for implementation & transformation

Sponsored by

Sponsored by Pfizer

Sponsored by

Sponsored by Pfizer

Pharmacy-based

vaccination and vaccine-

related services are linked

to 17 of the 21 FIP

Development Goals, with a

central role in seven of

them

Sponsored by

FIP President’s reflections: Dominique Jordan

Sponsored by

Sponsored by Pfizer

Sponsored by

Sponsored by Pfizer

Series 2 - Setting transformative goals

Setting transformative goals:

Deconstructing vaccination in pharmacy through the

FIP Development Goals (FIP DGs) across the entire

profession

Main outcome:

Discussing mechanisms and drivers to progress the

most relevant FIP Development Goals (FIP DGs) in

the context of transforming vaccination in pharmacy.

Sponsored by

Sponsored by Pfizer

Event title Date

Vaccination from specialist practice to every day practice:FIP DG 4 Advanced & Specialist Development

28th October 2020

Empowering pharmacists to deliver vaccination at the health-system level:FIP DG 7 Advancing Integrated Services

3rd November 2020

Removing policy barriers to pharmacist vaccinations:FIP DG 13 Policy Development

5th November 2020

Pharmacist vaccinators and communicable disease management:FIP DG 16 Communicable Diseases

10th November 2020

Sponsored by

Sponsored by Pfizer

Pharmacist vaccinators and antimicrobial stewardship:FIP DG 17 Antimicrobial Stewardship

11th November 2020

The Role of Pharmacist Vaccinators in improving access to and equity in healthcare outcomes:FIP DG 10 Equity & equality and FIP DG18 Access to Medicines & Services

17th November 2020

Pharmacist vaccinators and patient safety:FIP DG 19 Patient Safety

18th November 2020

Setting transformative goals for vaccination globally 25th November 2020

1.8 reviewing the fip transforming vaccination programme

Documents